Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of DS102 in Healthy Subjects
NCT02673593Phase 1Completed
- Sponsor
- DS Biopharma
- Start
- Jul 2015
- Primary completion
- Dec 2015
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of epeleuton in Nonalcoholic steatohepatitis (NASH), chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) (8 arms), sponsored by DS Biopharma. Primary endpoints: Safety of DS102 administered as a single dose at 14 days, Plasma concentrations assessed by Cmax of DS102 administered as a single dose at 14 days and 16 more. Started Jul 2015; status: completed.
02
Drugs
epeleuton
03
Conditions
Nonalcoholic steatohepatitis (NASH)chronic obstructive pulmonary disease (COPD)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02673593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02673593.